10-Q: DSwiss Reports Revenue Surge Amid Profit Decline & Control Woes

DSwiss, Inc. reported a significant revenue increase for the first half of 2025, but net income declined, raising going concern doubts and revealing material internal control weaknesses.

Summary

• Revenue for the six months ended June 30, 2025, surged to $2,022,526, a substantial increase from $1,050,744 in the same period of 2024.
• Despite higher revenue, net income for the six months ended June 30, 2025, decreased to $170,864 from $198,811 in the prior year.
• Gross profit increased to $411,655 for the six months ended June 30, 2025, but the gross margin significantly declined from 38.27% in 2024 to 20.35% in 2025.
• The company reported an accumulated deficit of $1,217,066 as of June 30, 2025, which raises substantial doubt about its ability to continue as a going concern.
• Material weaknesses in internal control over financial reporting were identified, including inadequate segregation of duties, ineffective risk assessment, and insufficient written policies for US GAAP and SEC guidelines.
• Cash and cash equivalents increased to $580,951 as of June 30, 2025, up from $397,476 at December 31, 2024.
• Operating cash flow decreased to $148,585 for the six months ended June 30, 2025, compared to $229,613 in the prior year.

Sentiment

Score: 3

Explanation: The sentiment is negative due to a significant decline in net income and gross margin despite strong revenue growth, coupled with a going concern warning and identified material weaknesses in internal controls. While cash position improved, the underlying profitability and governance issues are substantial concerns for financial stability and future performance.

Positives

• Revenue for the six months ended June 30, 2025, significantly increased to $2,022,526, nearly doubling from $1,050,744 in the same period of 2024.
• Gross profit for the six months ended June 30, 2025, rose to $411,655, up from $402,070 in the prior year.
• Cash and cash equivalents improved to $580,951 as of June 30, 2025, from $397,476 at December 31, 2024.
• Total stockholders' equity saw a substantial increase to $250,075 as of June 30, 2025, from $74,036 at December 31, 2024.
• The accumulated deficit was reduced to $1,217,066 as of June 30, 2025, from $1,387,930 at December 31, 2024.
• The company has successfully expanded its client base in OEM/ODM services and developed new products.
• Products are certified and approved by the Ministry of Health (MOH) Malaysia, indicating adherence to quality standards.

Negatives

• Net income for the six months ended June 30, 2025, decreased to $170,864, down from $198,811 in the prior year, despite significant revenue growth.
• Gross margin substantially declined to 20.35% for the six months ended June 30, 2025, from 38.27% in the same period of 2024.
• Operating cash flow decreased to $148,585 for the six months ended June 30, 2025, from $229,613 in the prior year.
• The accumulated deficit of $1,217,066 raises substantial doubt about the company's ability to continue as a going concern.
• Material weaknesses in internal control over financial reporting were identified, including inadequate segregation of duties, ineffective risk assessment, and insufficient written policies and procedures for accounting and financial reporting.

Risks

• The company's accumulated deficit of $1,217,066 raises substantial doubt about its ability to continue as a going concern, dependent on improving profitability and continued shareholder support.
• Material weaknesses in internal control over financial reporting, including inadequate segregation of duties and insufficient policies, pose a risk of material misstatements in financial statements.
• Significant customer concentration exists, with Customer C accounting for 60% of revenues and Customer A for 23% for the six months ended June 30, 2025.
• High vendor concentration is present, with Vendor B accounting for 57% of purchases and Vendor C for 12% for the six months ended June 30, 2025.
• Exposure to exchange rate risk due to operations in Malaysia and Hong Kong, where fluctuations in RM and HK$ against the US$ can impact reported income.
• Regulatory compliance risk as products require registration with the Drug Control Authority (DCA), Ministry of Health Malaysia, and non-compliance can lead to enforcement action.

Future Outlook

The company expects its growth to be driven primarily by its social media marketing strategy and plans to expand globally by forming strategic partnerships with local companies. Current capital resources are anticipated to meet basic operating requirements for approximately twelve months.

Management Comments

• Management believes existing shareholders or external financing will provide the additional cash to meet the company’s obligations as they become due.
• The increase in gross profits is attributed to the increase in revenue.
• Gross margins may not be comparable to those of other entities due to different inclusions in cost of revenue.
• The company's professionals manage the entire OEM/ODM process from custom formulation to shipping, including all necessary licenses.
• DSwiss has shown solid growth and is set to advance the biotechnology industry to drive nutraceutical and skincare biotechnology growth.
• While DSwiss has been focused almost exclusively upon pursuing operations within Asia, there are plans to expand outward and become a household name across the world.
• The company believes that forging strategic relationships and partnerships can expand operations globally at a greater pace and with greater certainty.

Industry Context

DSwiss, Inc. operates in the dynamic biotech-nutraceutical, beauty supplies, and medical consumables sectors, offering specialized turnkey private label manufacturing (OEM/ODM) services. The company's emphasis on certifications like GMP, FDA, HACCP, JAKIM HALAL, and Mesti highlights its commitment to quality and regulatory compliance, which is crucial in these health-related industries. Its strategic focus on social media marketing and global partnerships reflects a modern approach to market penetration and brand expansion, aligning with broader trends of digital engagement and collaborative growth models in the consumer health and beauty market.

Comparison to Industry Standards

• The filing explicitly states that the company's gross margins may not be comparable to those of other entities due to differences in how costs related to the distribution network are included in cost of revenue.
• No specific comparable companies, projects, or industry benchmarks are provided within the filing to allow for a detailed assessment against global standards.

Corporate Governance

Legal Proceedings

• No material, active or pending legal proceedings against the company were reported.
• The company is not involved as a plaintiff in any material proceedings or pending litigation.
• No proceedings were reported in which any directors, officers, affiliates, or beneficial shareholders are an adverse party or have a material interest adverse to the company.

Related Party Transactions

• Revenue from Related Party B (whose director is the company's founder) was $8,205 for the six months ended June 30, 2025, compared to $3,875 in the prior year.
• Professional fees paid to Related Party A (a wholly-owned subsidiary of a 7.33% shareholder) were $3,942 for the six months ended June 30, 2025, down from $5,230 in the prior year.
• Accounts payable to a related party amounted to $87 as of June 30, 2025, down from $818 at December 31, 2024.
• General and administrative expenses payable to a related party were $1,500 as of June 30, 2025, down from $3,000 at December 31, 2024.

Stakeholder Impact

• **Shareholders**: Face potential dilution if external equity financing is pursued to address going concern issues. The decline in net income and identified internal control weaknesses could negatively impact share price and investor confidence.
• **Employees**: No direct impact on employment mentioned, but the identified internal control weaknesses could indicate operational inefficiencies or increased scrutiny on financial processes.
• **Customers**: Benefit from the company's continued product development and quality certifications (MOH approved). However, high customer concentration poses a risk if key customer relationships deteriorate.
• **Suppliers/Vendors**: Continued business relationships, but the company's high vendor concentration means significant reliance on a few key suppliers, which could pose supply chain risks.
• **Creditors**: The going concern warning and increased liabilities may raise concerns about the company's ability to meet its financial obligations, potentially impacting future credit terms.

Next Steps

• Continue talent development and product research and development.
• Expand client base in OEM/ODM services.
• Launch new health and beauty projects.
• Implement and primarily utilize social media for marketing and customer engagement.
• Form strategic partnerships with local companies for global expansion.
• Address and remediate identified material weaknesses in internal control over financial reporting.

Key Dates

Recommendation

Despite significant revenue growth, the substantial decline in net income and gross margin indicates a deterioration in profitability and operational efficiency. The explicit 'going concern' warning, coupled with identified material weaknesses in internal control over financial reporting, signals significant financial and governance risks. A seasoned investor would view these issues as fundamental concerns that outweigh the top-line growth, suggesting a 'sell' recommendation until these critical issues are demonstrably resolved and sustained profitability is achieved.

Keywords

Nutraceutical, Biotechnology, Skincare, Medical Consumables, OEM/ODM, Malaysia, Hong Kong, SEC Filing, 10-Q, Financial Results, Going Concern, Internal Controls